Application of AMHR2 recombinant protein or fused protein in preparation of drugs for treating AMH signal axis abnormal activation related diseases
A technology of recombinant protein and fusion protein, which is applied in diseases, drug combinations, peptide/protein components, etc. It can solve the problems of unknown, undisclosed or prompted biological effects, and achieve excellent in vivo stability, long half-life, and binding force. strong effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0030] Construction and expression of embodiment 1.AMHR2 recombinant protein and AMHR2 fusion protein
[0031] The construction and expression of AMHR2 recombinant protein and AMHR2 fusion protein are briefly described as follows:
[0032] (1) AMHR2 (the amino acid sequence and nucleotide sequence of the polypeptide chain are shown in SEQ ID NO.1 and SEQ ID NO.4) and AMHR2-Fc (the amino acid sequence and nucleotide sequence of the polypeptide chain are shown in SEQ ID NO.4) synthesized from the whole gene shown in ID NO.2 and SEQ IDNO.5), AMHR2-Fc-LALAPG (the amino acid sequence and nucleotide sequence of the polypeptide chain are shown in SEQ ID NO.3 and SEQ IDNO.6), obtain AMHR2 recombinant protein and Two forms of AMHR2 fusion proteins.
[0033] (2) Expression and purification of recombinant proteins and fusion proteins
[0034] According to the literature (Hu S, et al.Science translational medicine, 2017,9(380):eaag0339; Finck B K.Science,265.; Mihara M et al..Journal of...
Embodiment 2
[0035] In vivo stability test of embodiment 2.AMHR2 recombinant protein and AMHR2 fusion protein
[0036] The half-life of AMHR2 recombinant protein and AMHR2 fusion protein was evaluated in NSG mice using the literature (Hu S, et al. Science translational medicine, 2017, 9(380): eaag0339.). The results showed that the in vivo half-lives of AMHR2, AMHR2-Fc, and AMHR2-Fc-LALAPG were 2.1 days, 9.6 days, and 9.1 days, respectively; the positive control cetuximab was 9.7 days; the negative control AMHR2 antigenic peptide (amino acid sequence PPNRRTCV) The half-life is too short to be measured. The results show that AMHR2 has certain druggability and can be used for in vivo research, and the fusion proteins AMHR2-Fc and AMHR2-Fc-LALAPG have better in vivo stability.
Embodiment 3
[0037] Embodiment 3.AMHR2 recombinant protein and / or AMHR2 fusion protein binding test
[0038] This example was carried out using the ELISA binding assay protocol described in the literature (Hu S, et al. Science translational medicine, 2017, 9(380): eaag0339.). The plating concentration of AMH protein (purchased from R&D Systems) was 10 μg / ml, and the concentration range of AMHR2, AMHR2-Fc, AMHR2-Fc-LALAPG protein pre-labeled with biotin was 0.01-100 ng / μL. After incubating AMH and then detecting and developing the color, the results are as follows: figure 1 shown. The three proteins have strong binding ability, and the control antigen peptide and cetuximab have no binding ability.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com